Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineArchived
The findings from Kreimer et al. need to be confirmed by other studies and require longer-term follow-up.
Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; for the CVT Vaccine Group. J Natl Cancer Inst. 2011 Sep 9. [Epub ahead of print]
Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest. The findings from Kreimer et al. need to be confirmed by other studies and require longer-term follow-up. However, if a one- or two-dose regimen of HPV vaccination does in fact elicit a good and durable immune response, these findings will have a great impact on costs and strategies for HPV vaccination programmes throughout Europe.
Conclusions of the eighteenth IHR Emergency Committee do not change the ECDC risk assessment for Europe concerning polio
26 Sep 2018 - Statement of the Eighteenth IHR Emergency Committee Regarding the International Spread of Poliovirus, 15 August 2018
ECDC comment: European Commission updates communicable disease surveillance list - Lyme neuroborreliosis now under EU/EEA surveillance
2 Aug 2018 - ECDC will start monitoring disease distribution in the EU and collecting EU data through the epidemiological surveillance network comprising the European Commission, ECDC and national authorities for epidemiological surveillance.
The benefits of HIV treatment: undetectable means you do not pass on the virus
25 Jul 2018 - Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.